Examination about the pharmacokinetics of the dexamethasone under the Fosaprepitant medication to the nausea and vomiting of a high emetic risk chemotherapy.

Trial Profile

Examination about the pharmacokinetics of the dexamethasone under the Fosaprepitant medication to the nausea and vomiting of a high emetic risk chemotherapy.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Fosaprepitant (Primary) ; Dexamethasone; Palonosetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics
  • Acronyms PROEMEND PK
  • Most Recent Events

    • 01 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top